Award4

CRISPR Therapeutics AG

Total Value

$4.7M

Filing Date

Nov 6, 2026

1 transactions

Trade Summary

On Nov 4, 2026, Sakhamuri Sivakesava, Insider, reported $4.7M of CRISPR Therapeutics AG (CRSP) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $51.78. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Sakhamuri Sivakesava
Role: Insider
Location: BOSTON, MA

Filing Details

Filing Date: Nov 6, 2026
Transaction Date: Nov 4, 2026
Accession Number: 0001193125-26-452143
Form Type: 4

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Nov 4, 2026	CRSP derivative	90,000	$51.78	Grant/Award	$4.7M
Nov 4, 2026	CRSP derivative	40,000	—	Grant/Award	—

Want live alerts when Sakhamuri Sivakesava trades again?

Download Insider Trades to track CRSP, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
(F2)Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
(F3)This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sakhamuri Sivakesava

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

02127

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$51.78	11/04/2026		A		90,000		⁽¹⁾	11/04/2036	Common Shares	90,000	$0	90,000	D
Restricted Stock Units	⁽²⁾	11/04/2026		A		40,000		⁽³⁾	⁽³⁾	Common Shares	40,000	$0	40,000	D

Explanation of Responses:

1. This option was granted on November 4, 2026 with respect to 90,000 Common Shares. 25% of the shares shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. This restricted stock unit award was granted on November 4, 2026 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on November 2, 2027, (ii) one quarter of the shares vesting on November 2, 2028, (iii) one quarter of the shares vesting on November 2, 2029, and (iv) one quarter of the shares vesting on November 2, 2030.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001193125-26-452143.

CRISPR Therapeutics AG

Trade Summary

Company Information

Insider Information

Filing Details

Derivative Transactions

Want live alerts when Sakhamuri Sivakesava trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4